Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Intensity Allo-HSCT for High-Risk Neuroblastoma
NCT00874315Phase 2Withdrawn
- Sponsor
- Nationwide Children's Hospital
- Start
- Sep 2008
- Primary completion
- Jun 2012
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic hematopoietic stem cells in neuroblastoma, sponsored by Nationwide Children's Hospital. Primary endpoint: Feasibility of allogeneic hematopoietic stem cell transplantation. Planned start Sep 2008; status: withdrawn.
02
Drugs
allogeneic hematopoietic stem cells
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT00874315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00874315.